BridgeBio Pharma Inc (BBIO)vsInsmed Inc (INSM)
BBIO
BridgeBio Pharma Inc
$71.61
+4.49%
HEALTHCARE · Cap: $13.29B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 21% more annual revenue ($606.42M vs $502.08M). INSM leads profitability with a -2.1% profit margin vs -144.4%. INSM earns a higher WallStSmart Score of 39/100 (F).
BBIO
Avoid31
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 25.2% year-over-year
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of -17.9% — below average capital efficiency
Negative free cash flow — burning cash
Distress zone — elevated risk
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : BBIO
The strongest argument for BBIO centers on Debt/Equity, Revenue Growth. Revenue growth of 25.2% demonstrates continued momentum.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : BBIO
The primary concerns for BBIO are EPS Growth, Return on Equity, Free Cash Flow.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
BBIO profiles as a growth stock while INSM is a turnaround play — different risk/reward profiles.
BBIO carries more volatility with a beta of 1.18 — expect wider price swings.
BBIO is growing revenue faster at 25.2% — sustainability is the question.
BBIO generates stronger free cash flow (-61M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 31/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BridgeBio Pharma Inc
HEALTHCARE · BIOTECHNOLOGY · USA
BridgeBio Pharma, Inc. is dedicated to the discovery, development and supply of various drugs for genetic diseases. The company is headquartered in Palo Alto, California.
Visit Website →Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?